

Drugs approved by USFDA in 2016

K Parushuram naik¹, V Sai lakshmi², J Jyothirmai³

^{1,2}Assistant Professor, ³Professor, Department of Pharmacology, Prathima Institute of Medical Sciences, Nagunur, Karimnagar, Telangana, India.

Address for Correspondence: Dr. K. Parushuram Naik, Assistant Professor, Department of Pharmacology, Prathima Institute of Medical Sciences, Nagunur, Karimnagar, Telangana, India.

Email id: kprnaik2k10@gmail.com

S.No	Drug Name	Active ingredient	Indication	Dose	Route of administration
1	Zepatier	Elbasvir and Grazoprevir. ¹	Chronic Hepatitis C genotypes 1 or 4 infection in adult.	One tablet once daily for 12 Wks (50 mg elbasvir and 100 mg grazoprevir).	Oral.
2	Briviact	Brivaracetam. ²	Adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.	25-50mg twice daily.	Oral and Intravenous
3	Anthim	Obiltoximab. ³	Inhalational anthrax due to B. anthracis.	Adult Patients: 16 mg/kg. Pediatric Patients: Greater than 40 kg: 16 mg/kg, Greater than 15 kg to 40 kg: 24 mg/kg, Less than or equal to 15 kg: 32 mg/kg	Intravenous
4	Taltz	Ixekizumab. ⁴	Adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.	160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.	Subcutaneous
5	Cinqair	Reslizumab. ⁵	Severe asthma	3 mg/kg once every 4 weeks by intravenous infusion over 20-50 minutes.	Intravenous
6	Defitelio	Defibrotide sodium. ⁶	Adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).	6.25 mg/kg every 6 hours given as a 2-hour IV infusion, for a minimum of 21 days. If after 21 days signs and symptoms of VOD have not resolved, continue treatment until resolution	Intravenous
7	Venclexta	Venetoclax. ⁷	Chronic lymphocytic leukemia in patients with a specific chromosomal abnormality	20 mg once daily for 7 days, followed by a weekly ramp-up dosing schedule to the recommended daily dose of 400 mg.	Oral

8	Nuplazid	Pimavanserin. ⁸	Hallucinations and delusions associated with Parkinson's disease psychosis.	34 mg, taken orally as two 17 mg tablets once daily, without titration.	Oral.
9	Tecentriq	Atezolizumab. ⁹	Locally advanced or metastatic urothelial carcinoma.	1200 mg as an IV infusion over 60 minutes every 3 weeks.	Intravenous
10	Zinbryta	Daclizumab. ¹⁰	Multiple sclerosis.	150 milligrams once monthly.	Subcutaneous
11	Ocaliva	Obeticholic acid. ¹¹	Chronic liver disease.	5 mg orally once daily in adults.	Oral.
12	Axumin	Fluciclovine F 18. ¹²	A new diagnostic imaging agent to detect recurrent prostate cancer.	370 MBq (10 mCi) as a bolus intravenous injection.	Intravenous
13	Netspot	Gallium Ga 68 dotatate. ¹³	A diagnostic imaging agent to detect rare neuroendocrine tumors	2 MBq/kg of body weight (0.054 mCi/kg) up to 200 MBq (5.4 mCi) administered as IV bolus injection.	Intravenous
14	Epclusa	Sofosbuvir and velpatasvir. ¹⁴	To treat all six major forms of Hepatitis C virus.	One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken once daily.	Oral.
15	Xiidra	Lifitegrast ophthalmic solution. ¹⁵	To treat the signs and symptoms of dry eye disease.	One drop twice daily in each eye.	Topical. EYE.
16	Adlyxin	Lixisenatide. ¹⁶	To improve glycemic control in adults with Type 2 diabetes mellitus.	Initiate at 10 mcg once daily within one hour before the first meal of the day for 14 days. On Day 15, increase dosage to 20 mcg once daily.	Subcutaneous
17	Exondys 51	Eteplirsen. ¹⁷	Duchenne muscular dystrophy.	30 milligrams per Kg of body weight once weekly, infusion over 35 to 60 minutes.	Intravenous
18	Lartruvo	Olaratumab. ¹⁸	Soft tissue sarcoma.	15 mg/kg as an infusion over 60 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity.	Intravenous
19	Zinplava	Bezlotoxumab. ¹⁹	To reduce the recurrence of Clostridium difficile infection in patients aged 18 years or older.	Single dose of 10 mg/kg administered as an infusion over 60 minutes.	Intravenous

REFERENCES

1. https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf.
2. <https://www.briviact.com/briviact-PI.pdf>.
3. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125509lbl.pdf
4. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf
5. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf
6. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208114lbl.pdf
7. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf
8. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf
9. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761034s000lbl.pdf
10. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761029s000lbl.pdf
11. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
12. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208054s000lbl.pdf
13. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208547s000lbl.pdf
14. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208341s000lbl.pdf
15. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208073s000lbl.pdf
16. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471Orig1s000lbl.pdf
17. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206488lbl.pdf
18. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761038lbl.pdf
19. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761046s000lbl.pdf

Please cite this article as: K P R Naik, Sai lakshmi V, Jyothirmai J. Drugs Approved by USFDA in 2016. Perspectives in medical research 2017;5(1):86-88.

Sources of Support: Nil, Conflict of interest: None declared.